Affineon Health

The agent is the product. Affineon sells nothing that functions without the model: a multi agent system reads inbound lab results and renewal requests, classifies clinical significance, drafts patient messages and routes what needs a human. Remove the AI and no workflow tool, data asset or network remains underneath it.

Better described than most of this category, and still missing the number that matters. Affineon publishes its routing rule: normal, insignificantly abnormal and CC'd results are handled automatically around the clock, while results needing clinical review are summarised and trended for the provider instead. The protocols deciding which is which are configurable per practice, so the organisation defines the threshold rather than the vendor, the same property that earned Haystack a better grade than its peers elsewhere in this index. What is not published is any measure of how often the gate is wrong: no false negative rate, no sampling or audit disclosure, no published definition of insignificantly abnormal, and no stated behaviour on a borderline result. That is this category's defining failure mode, mistriage, sitting on a product whose own page describes its job as automating the inbox items a provider does not want to see. Held at B for describing the gate and devolving control of it. A requires publishing how often the gate misses.

Described as a multi agent and agentic AI platform with no further detail. No model is named, no model card exists, there is no statement of whether foundation models are first party or licensed, and no published methodology for how clinical significance is classified. The standing whose model is it question, which OmniMD answers plainly elsewhere in this index, goes unanswered here.

All evidence is vendor generated. Two published case studies name the practice and the clinician, and a long testimonial set names individual physicians with credentials, which is more attribution than most of this market offers. There is no peer reviewed study, no third party evaluation and no controlled comparison. The headline figures also disagree with each other on the same site: the hero states a 50 to 60 percent inbox reduction, the summary badge and press releases state 30 to 80 percent, and a customer administrator quote states 40 to 45 percent for laboratory workload specifically. Ranges that wide, with no stated denominator or measurement method, are marketing claims rather than evidence. Graded C on the standing precedent that deployment reports do not substitute for a study.

The published privacy policy is a generic marketing website policy, effective 14 December 2023, which predates the product launch. It covers name, email, phone, IP address and cookies. It contains no provision on protected health information, laboratory data, patient messages, retention, de identification, or whether customer data trains models, for a product that ingests lab results and drafts patient communications. It also carries a marketing identity resolution clause disclosing that online data partners may associate site activity with other personal information held about the visitor, with a Retention.com opt out link. That clause governs website visitors and not patients, and this record should not be read as suggesting otherwise. Graded C rather than lower on the same discipline applied to Regard: nothing here establishes mishandling, enterprise PHI is governed by the business associate agreement and the customer's own security review rather than by a website policy, and named practices are running the product in production. The grade describes the public disclosure surface, which is thin.

HIPAA compliance is asserted on the home page alongside a compliance badge. No business associate agreement is published, no terms are described, and nothing states whether a BAA is included or priced separately. That places Affineon on the middle rung of this index's HIPAA ladder, where most of the market sits: compliance claimed, instrument unpublished. The rungs above are a BAA explicitly included at no extra cost, coverage that is automatic and universal, and publication of the BAA text itself.

An AICPA SOC badge is displayed and the site states the company is SOC 2 and HIPAA compliant. This is the company's own attestation rather than a hosting provider's, materially better than the certified data centres formulation on this index's watchlist. Two gaps hold it at B. The type is not specified, and Type I versus Type II is the question this index asks of every SOC 2 claim, since Type I describes controls at a point in time while Type II tests their operation over a period. There is also no trust centre, no report request path and no other named certification. A precision note that does not move the grade: SOC 2 produces an attestation report, so both compliant and certified are loose wording for it.

No clearance, no submission and no published regulatory analysis, and none is obviously required. Recorded as an observation with an ask rather than as a finding: the product autonomously classifies the clinical significance of a laboratory result and generates patient facing messages about it, which sits closer to the clinical decision support boundary than a pure routing tool does. Whether it falls within the software functions excluded from device regulation under the 21st Century Cures Act turns on whether a clinician can independently review the basis for the output, which is precisely the analysis a buyer should ask Affineon to have documented rather than assume.

No fairness, subgroup or performance variation disclosure of any kind, and the product design makes the absence consequential. When a system removes results from human review, any systematic miss lands on the patients whose results were never read, and nobody is positioned to notice it. That is the same structural argument this index applies to autonomous reporting in radiology. Separately, the revenue framing on the site, drive new revenue for your practice, appears to describe throughput created by freeing clinician time rather than coding intensity, so it is not placed on this index's coding gradient. The mechanism is not stated anywhere and a buyer should establish it.

Deep but narrow. Affineon runs inside the EHR rather than as a separate application, requires no new app or workflow change by its own account, and is listed and rated on the athenahealth Marketplace, which is evidence of a working production integration rather than an asserted one. athenahealth is nonetheless the only integration named anywhere on the site. Buyers on any other EHR should establish availability before evaluating anything else, and the Embed white label programme suggests distribution through partner products may be the route to other systems rather than direct integration.

Cloud delivered and integrated into the EHR, with no statement of hosting provider, region, data residency, tenancy model, or any single tenant or on premise option. Nothing was located describing where lab results and patient messages are processed or how long they persist.

Among the clearest commercial disclosures in the index. Affineon publishes a complete price ladder on its public site with no contact sales gate: 100, 95, 80 and 75 US dollars per provider per month for Labs Core or Rx Renewals individually across four volume bands covering 1 to 249 providers, and 175, 165, 155 and 145 US dollars per provider per month for the bundle of both, with 250 or more providers quoted as enterprise. Publishing the per module rate, the bundled rate and the volume breakpoints together lets a practice calculate its own cost before speaking to anyone, which almost nothing else in this category permits. The site also advertises a risk free trial with a satisfaction guarantee, though the terms of that guarantee are not published.

Scoped to ambulatory practice and to two workflows rather than to the whole inbox. Published pricing bands run from a single provider to 250 and above, so the commercial model addresses solo practice through enterprise, and the named customer evidence is primary care and internal medicine. Affineon states it has processed more than 2,000 distinct laboratory types, a genuine breadth claim within its scope. No inpatient, emergency or specialty specific coverage is described, and inbox items outside labs and renewals, including general patient portal messages and staff messages, are not claimed.